Supplementary Fig S5 from Heme Sequestration As an Effective Strategy for the Suppression of Tumor Growth and Progression

Figure S5. HeSP treatment effectively inhibits transporters and key enzymes in glucose and glutamine metabolism in subcutaneous NSCLC tumor xenografts. A, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC2A1 in control and HeSP-treated tumors. B, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of HK2 in control and HeSP-treated tumors. C, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of SLC1A5 in control and HeSP-treated tumors. D, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of GLS in control and HeSP-treated tumors. Shown are montages and 10X images of control and HeSP-treated tumor tissue sections stained with DAPI (row 1) or antibodies against the indicated protein (row 2) or merged images of DAPI and the indicated protein (row 3). The white rectangles in DAPI images denote the regions shown in 10X images. Scale bar, montage, 1 mm; 10X, 200 μm. Protein levels were quantified, and data were plotted as mean {plus minus} SEM. ***, P < 0.005.